Japan's pharmaceutical company Eisai is set to launch its innovative Alzheimer's drug Leqembi in China, targeting 1,500 patients for its initial rollout later this year. The company anticipates a 'huge' surge in growth starting in 2025, which is expected to be driven by changes in diagnostic practices for Alzheimer's disease in the country.
Eisai expects 1,500 Alzheimer's patients in China launch: Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025… https://t.co/P98zfFQSDi #japannews #japantoday
Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, according to a company spokesperson. https://t.co/jyaVYqHW24
Exclusive: Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change https://t.co/g8SQ9wrq3s
Eisai Expects 1,500 Alzheimer's Patients in China Launch, Sees Huge Growth. $BIIB $ESALF $LLY https://t.co/Xz5jZ1NzS3
Exclusive: Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth https://t.co/voupyhu7gu https://t.co/wlDsUWdO6e